Efficacy of Ubiquinone and Combined Antioxidant Therapy in Non-proliferative Diabetic Retinopathy

Efficacy of Ubiquinone and Combined Antioxidant Therapy on Progression, Oxidative Stress Markers and Mitochondrial Dysfunction in Non-proliferative Diabetic Retinopathy: A Phase 2a Randomized Double-blind Placebo-controlled Study

The purpose of this study is to evaluate the efficacy of ubiquinone and combined antioxidant therapy on progression, clinical regression, oxidative stress markers and mitochondrial dysfunction in non-proliferative diabetic retinopathy.

The investigators are interested in demonstrating the efficacy of Ubiquinone and combined antioxidant therapy in the pharmacological management of diabetic retinopathy since early stages.

Inclusion Criteria:

• Patients with type 2 diabetes mellitus
• Patients with non proliferative diabetic retinopathy
• Glycated hemoglobin < 12.0%
• Signing of informed consent

Exclusion Criteria:

• Patients with clinically significant macular edema
• Patients with diabetic retinopathy advanced lesions that have required or require specific treatment (laser, vitrectomy)
• Pretreatment with argon laser or excimer laser Ophthalmology surgery
• Any other associated ocular pathology (glaucoma, cataracts, changing cornea dystrophy, macular degeneration)
• Pregnancy, lactation, inadequate use of contraception
• Antioxidant drug and/or supplements six months previous to enrollment
• Renal and/or hepatic failure
• Age under 30 or over 75 years
• Severe cardiovascular disease (myocardial infarction, stroke, severe peripheral vasculopathy)
• Blood dyscrasias
• Have or have had cancer or other serious illness
• Neurodegenerative process
• Allergy to vitamins